CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

219 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BBRAFV600KPredictiveSupportsSensitivity/ResponseMelanomaDabrafenib,TrametinibLarkin et al., 2014
BBRAFV600EPredictiveSupportsSensitivity/ResponseAnaplastic Thyroid CarcinomaTrametinib,DabrafenibSubbiah et al., 2018
BBRAFV600EPrognosticSupportsPoor OutcomeColorectal CancerRoth et al., 2010
BBRAFV600EPrognosticSupportsPoor OutcomeColorectal CancerVan Cutsem et al., 2011
BBRAFMutationPrognosticSupportsPoor OutcomeColorectal CancerMaughan et al., 2011
BBRAFMutationPrognosticSupportsPoor OutcomeColorectal CancerClancy et al., 2013
BBRAFV600EPrognosticSupportsPoor OutcomeChildhood Low-grade GliomaYang et al., 2018
BBRAFV600EPredictiveSupportsSensitivity/ResponseLangerhans Cell SarcomaVemurafenibDonadieu et al., 2019
CBRAFV600 AND BRAF AmplificationPredictiveSupportsResistanceMelanomaDabrafenib,TrametinibLong et al., 2014
BBRAFNon-V600PredictiveDoes Not SupportSensitivity/ResponseSolid TumorTrametinibJohnson et al., 2020
BBRAFV600EPredictiveSupportsSensitivity/ResponsePapillary Thyroid CarcinomaVemurafenibBrose et al., 2016
BBRAFV600EPrognosticSupportsPoor OutcomePapillary Thyroid CarcinomaXing et al., 2005
ABRAFV600PredictiveSupportsSensitivity/ResponseMelanomaAtezolizumab,Vemurafenib,CobimetinibGutzmer et al., 2020
ABRAFV600EPredictiveSupportsSensitivity/ResponseSolid TumorTrametinib,DabrafenibSubbiah et al., 2023
ABRAFV600EPredictiveSupportsSensitivity/ResponseLow Grade GliomaDabrafenib,TrametinibBouffet et al., 2023
BBRAFV600EDiagnosticSupportsPositiveThyroid CancerHowell et al., 2011
DBRAFV600EPredictiveDoes Not SupportResistanceMelanomaMirdametinib,TrametinibNissan et al., 2014
BBRAFV600PredictiveSupportsResistanceColorectal CancerPanitumumabPeeters et al., 2013
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerPanitumumab,SorafenibDi Nicolantonio et al., 2008
DBRAFV600E AND NF1 LossPredictiveSupportsResistanceMelanomaVemurafenibNissan et al., 2014
BBRAFV600PredictiveSupportsSensitivity/ResponseMelanomaTrametinib,DabrafenibFlaherty et al., 2012
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerPLX4720,Pictilisib BismesylateRad et al., 2013
DBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaNutlin-3,PLX4720Ji et al., 2013
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerCapecitabine,Bevacizumab,VemurafenibYang et al., 2012
BBRAFV600EPrognosticSupportsPoor OutcomeMelanomaNagore et al., 2014
BBRAFV600EPrognosticSupportsPoor OutcomePapillary Thyroid CarcinomaHowell et al., 2011
BBRAFV600EPrognosticSupportsPoor OutcomePapillary Thyroid CarcinomaHe et al., 2014
BBRAFV600EPrognosticSupportsPoor OutcomePapillary Thyroid CarcinomaHowell et al., 2011
BBRAFV600EPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
BBRAFV600EPrognosticSupportsPoor OutcomeMultiple MyelomaAndrulis et al., 2013
DBRAFV600EPredictiveSupportsSensitivity/ResponseCancerCobimetinibHatzivassiliou et al., 2013
DBRAFL485_P490delPredictiveSupportsSensitivity/ResponseCancerPan-RAF Inhibitor LY3009120Chen et al., 2016
CBRAFV600KPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibSahadudheen et al., 2016
BBRAFMutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerPanitumumab,CetuximabPietrantonio et al., 2015
BBRAFV600EPredictiveSupportsReduced SensitivityColorectal CancerDabrafenibFalchook et al., 2012
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,Cetuximab,GefitinibPrahallad et al., 2012
BBRAFV600EPredictiveSupportsSensitivity/ResponseSkin MelanomaVemurafenibSosman et al., 2012
BBRAFV600EPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerPanitumumab,VemurafenibYaeger et al., 2015
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerGDC-0879,DactolisibCoffee et al., 2013
CBRAFV600EPredictiveSupportsSensitivity/ResponseGastrointestinal Neuroendocrine TumorTrametinib,Vemurafenib,DabrafenibKlempner et al., 2016
EBRAFD594APredictiveSupportsSensitivity/ResponseSkin MelanomaSorafenib,Mitogen-Activated Protein Kinase Kinase InhibitorHeidorn et al., 2010
EBRAFD594VPredictiveSupportsSensitivity/ResponseSkin MelanomaTrametinib,SorafenibHeidorn et al., 2010
EBRAFK483MPredictiveSupportsSensitivity/ResponseSkin MelanomaSorafenib,Mitogen-Activated Protein Kinase Kinase InhibitorHeidorn et al., 2010
CBRAFL597SPredictiveSupportsSensitivity/ResponseSkin MelanomaMEK Inhibitor REC-4881Dahlman et al., 2012
DBRAFK601EPredictiveSupportsSensitivity/ResponseSkin MelanomaVemurafenib,TrametinibDahlman et al., 2012
CBRAFL597VPredictiveSupportsSensitivity/ResponseSkin MelanomaTrametinibFalchook et al., 2012
BBRAFV600EPrognosticSupportsPoor OutcomeColorectal CancerAmaki-Takao et al., 2016
BBRAFV600PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaVemurafenibHyman et al., 2015
BBRAFV600PredictiveSupportsSensitivity/ResponseLangerhans-cell HistiocytosisVemurafenibHyman et al., 2015
BBRAFV600PredictiveSupportsResistanceColorectal CancerVemurafenibHyman et al., 2015
Page 2 of 5
PreviousNext